Data as of 1:57pm ET
| +0.10 / +6.94%|
Cellceutix Corp. is an emerging bio-pharmaceutical company, which focuses on the development of its pipeline of compounds targeting areas of unmet medical need. It flagship compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers. The company also owns the rights to seven other drug compounds, including KM-133, which is in development for psoriasis, and KM-391 for the treatment of the core symptoms of autism. Cellceutix was founded on August 1, 2005 and is headquartered in Beverly, MA.
|Leo Ehrlich||Chairman, CEO, CFO, Secretary, Director & CAO|
|Krishna Kumar Menon||President, Director & Chief Scientific Officer|